Journal article

GENERALIZED IMMUNE ACTIVATION IN STRUCTURES RELATED TO PMR OR GCA ON PET/CT ASSESSMENT DOES NOT OCCUR IN IMMUNE CHECKPOINT INHIBITOR-TREATED PATIENTS WHO DO NOT GO ON TO DEVELOP RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS

D Liew, A Poon, C Mcmaster, C Owen, J Leung, A Frauman, J Cebon, A Scott, R Buchanan

ANNALS OF THE RHEUMATIC DISEASES | BMJ PUBLISHING GROUP | Published : 2021

Abstract

Background:The pathogenesis of rheumatic immune-related adverse events (irAEs) from checkpoint inhibitor cancer immunotherapy directed against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) remains unknown, even though they are a consequence of pharmacologic inhibition of a specific immune mechanism. Given that some irAEs resemble polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), a disease whose pathogenesis is poorly understood, observations regarding the pathogenesis of PMR-like or GCA-like irAEs are of significant interest. One proposed pathogenic mechanism involves generalized immune activation leading to a spectrum of subclinical disease. Interrog..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

David Liew is the recipient of the Ronald John Gleghorn Bursary from the University of Melbourne.